Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.15 (market cap $162.00B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 75.7× Recursion Pharmaceuticals Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IEMG | RXRX | |
|---|---|---|
Market Cap | $162.00B | $2.14B |
Volume | 13,446,151 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $6.79 |
52-Week Low | $64.22 | $2.84 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.14, down 1.1% with a bearish technical signal from moving averages. The ETF's emerging markets focus has delivered strong recent performance, with articles highlighting 35% one-year returns and record asset inflows. Technical indicators show neutral oscillators but bearish momentum, with key support at $79 and resistance at $82.
Emerging markets exposure offers growth potential amid dollar weakness, though higher volatility and expense ratios compared to developed market ETFs present risks. The fund's 39% technology weighting and outperformance versus peers like SCHE and VWO provide differentiation, but concentration risks and market sensitivity require careful monitoring.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
